Space Industry and Business News  
SPACE MEDICINE
Investigation Tests Drug to Activate Immune System, Help Fight Cancer
by Jenny Howard for ISS Science News
Houston TX (SPX) Jun 16, 2017


The cancer cells will be cultured within the six-well BioCell, featured above, created by BioServe Space Technologies. Credits: BioServe Space Technologies

On Earth, research into antibody-drug conjugates to treat cancer has been around a while. The research presents a problem, though, because Earth-based laboratories aren't able to mimic the shape of the cancer cell within the body, which can sometimes produce incorrect findings. The International Space Station's unique microgravity environment allows scientists to approach the research from a new, 3-D angle.

The Efficacy and Metabolism of Azonafide Antibody-Drug Conjugates (ADCs) in Microgravity investigation seeks to activate immunogenic cell death within the cancer cells, which should kill the cancer and prevent the disease from reoccurring in the future. The experiment explores a new drug and antibody combination that may increase the effectiveness of the treatment and decrease secondary side effects associated with chemotherapy.

"In space, you can grow larger and larger cancer tumors spherical in shape, so you have a better model of what's happening in the human body," said Luis Zea, research associate for Bioserve Space Technologies. "The chances of having false negatives or false positives is decreased."

Knowing how drug combinations work in microgravity is increasingly important as we plan for future deep-space missions, where we may need to be able to treat diseases such as cancer.

"We don't know if the cells will be metabolizing the drug at the same rate as they do on Earth," said Dhaval Shah, co-investigator. "In the long term, we need to be sure what drugs are going to work."

To treat cancer currently, chemotherapy works by orally and intravenously injecting the patient with a drug to attack and kill cancer cells. Unfortunately, this untargeted approach also kills healthy cells.

The ADCs investigation is a combination of two molecules: a cancer-killing Azonafide drug and an antibody, which may enable a targeted approach for cancer treatment by only allowing the drug to kill cancer cells, while leaving the healthy cells intact.

"One of the reasons cancer cells grow in certain individuals is their defense mechanism fails to recognize them," said Shah. "This molecule also has the ability to wake up, or release the break, on existing immune cells within the cancer. In any given tumor, when these molecules are released [from the cancer cell], they 'wake up' the surrounding immune cells and stimulate the body's own immune system, making it recognize and kill the cancer cells itself."

Cancer patients receiving chemotherapy often experience side effects such as nausea, fatigue, hair loss, cognitive impairment, and more during the course of treatment. Although this combination may decrease many of the negative side effects of chemotherapy, it may also have its own side effects, though potentially less severe and short-lived.

"The antibody is like a connector block," said Zea. "On one side it will only bind to the drug and the other side, may only bind to cancer cells and not healthy cells. So by combining these two, the idea is to decrease the nasty side effects of chemotherapy."

SPACE MEDICINE
Cell Cultures Go For the Gold
Houston TX (SPX) Jun 09, 2017
A wide variety of research relies on growing cells in culture on Earth, but handling these cells is challenging. With better techniques, scientists hope to reduce loss of cells from culture media, create cultures in specific shapes, and improve retrieval of cells for analysis - all of which would improve experiment results. Handling cells in microgravity poses even greater challenges, and with o ... read more

Related Links
The Efficacy and Metabolism of Azonafide Antibody-Drug Conjugates(ADCs) in Microgravity
Space Medicine Technology and Systems


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


Comment using your Disqus, Facebook, Google or Twitter login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

SPACE MEDICINE
The first nanometrically-sized superelastic alloy

Cloudy with a chance of radiation: NASA studies simulated radiation

Oyster shells inspire new method to make superstrong, flexible polymers

New technique enables 3-D printing with paste of silicone particles in water

SPACE MEDICINE
Harris Corp. awarded Special Forces radio contract

Airbus provides German troops with support communications at 15 sites worldwide

Airbus further extends channel partner program for military satellite communications in Asia

Radio communications have surprising influence on Earth's near-space environment

SPACE MEDICINE
SPACE MEDICINE
Galileo grows: two more satellites join working constellation

BDS Precise Service System covers over 300 Chinese cities

GIS is a powerful tool that should be used with caution

Japan launches satellite in bid for super accurate GPS system

SPACE MEDICINE
KC-46A tanker receives electronic testing

Boeing receives contract for F-18, magnetic launch system support

Debris from Myanmar military plane found in sea

F-35 flights grounded at Arizona base because of health concerns

SPACE MEDICINE
Researchers image quasiparticles that could lead to faster circuits, higher bandwidths

Nitrides in Transition

Seeing the invisible with a graphene-CMOS integrated device

Building 'OLEDs' from the ground up for better electronics

SPACE MEDICINE
NASA satellites image, measure Florida's extreme rainfall

The heat is on for Sentinel-3B

exactEarth Launches Revolutionary Global Real-Time Maritime Tracking and Information Service

Earth is a jewel, says astronaut after six months away

SPACE MEDICINE
'Green police' to battle Tunisia trash scourge

Garbage dumped in sea off Lebanon sparks outrage

Plastic in rivers major source of ocean pollution: study

A new hyper-local air pollution map









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.